p.96 抽出テキスト

hypertension after repair of mitral valve prolapse. J Am Coll Cardiol 2015;65:1931–8. https://doi.org/10.1016/j.jacc.2015.01.059 732. Chang JD, Manning WJ, Ebrille E, Zimetbaum PJ. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol 2017;69: 2331–41. https://doi.org/10.1016/j.jacc.2017.02.055 733. von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M, et al. Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the transatlantic TRILUMINATE trial. Circ Cardiovasc Interv 2023;16:e012888. https://doi. org/10.1161/CIRCINTERVENTIONS.122.012888 734. Lurz P, Besler C, Schmitz T, Bekeredjian R, Nickenig G, Möllmann H, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol 2023;82: 281–91. https://doi.org/10.1016/j.jacc.2023.05.008 735. Kodali SK, Hahn RT, Davidson CJ, Narang A, Greenbaum A, Gleason P, et al. 1-Year outcomes of transcatheter tricuspid valve repair. J Am Coll Cardiol 2023;81:1766–76. https://doi.org/10.1016/j.jacc.2023.02.049 736. Kar S, Makkar RR, Whisenant BK, Hamid N, Naik H, Tadros P, et al. (March 30, 2025) Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: the TRILUMINATE pivotal randomized trial. Circulation, https://doi.org/10. 1161/CIRCULATIONAHA.125.074536 737. Donal E, Dreyfus J, Leurent G, Coisne A, Leroux PY, Ganivet A, et al. Transcatheter edge-to-edge repair for severe isolated tricuspid regurgitation: the Tri.Fr randomized clinical trial. JAMA 2025;333:124–32. https://doi.org/10.1001/jama.2024.21189 738. Hahn RT, Makkar R, Thourani VH, Makar M, Sharma RP, Haeffele C, et al. Transcatheter valve replacement in severe tricuspid regurgitation. N Engl J Med 2024;392:115–26. https://doi.org/10.1056/NEJMoa2401918 739. Park SJ, Gentry JLI, Varma N, Wazni O, Tarakji KG, Mehta A, et al. Transvenous extraction of pacemaker and defibrillator leads and the risk of tricuspid valve regurgitation. JACC Clin Electrophysiol 2018;4:1421–8. https://doi.org/10.1016/j.jacep.2018.07.011 740. Aboulhosn J, Cabalka AK, Levi DS, Himbert D, Testa L, Latib A, et al. Transcatheter valve-in-ring implantation for the treatment of residual or recurrent tricuspid valve dysfunction after prior surgical repair. JACC Cardiovasc Interv 2017;10:53–63. https:// doi.org/10.1016/j.jcin.2016.10.036 741. Chen S, Dershowitz L, George I. Transcatheter valve implantation for degenerated tricuspid bioprosthesis and failed tricuspid ring. Ann Cardiothorac Surg 2021;10:651–7. https://doi.org/10.21037/acs-2021-tviv-11 742. Rao VN, Giczewska A, Chiswell K, Felker GM, Wang A, Glower DD, et al. Long-term outcomes of phenoclusters in severe tricuspid regurgitation. Eur Heart J 2023;44: 1910–23. https://doi.org/10.1093/eurheartj/ehad133 743. Van de Veire NR, Braun J, Delgado V, Versteegh MI, Dion RA, Klautz RJ, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J Thorac Cardiovasc Surg 2011;141:1431–9. https://doi.org/10.1016/j.jtcvs.2010.05.050 744. Brescia AA, Ward ST, Watt TMF, Rosenbloom LM, Baker M, Khan S, et al. Outcomes of guideline-directed concomitant annuloplasty for functional tricuspid regurgitation. Ann Thorac Surg 2020;109:1227–32. https://doi.org/10.1016/j.athoracsur.2019.07.035 745. Hamandi M, Smith RL, Ryan WH, Grayburn PA, Vasudevan A, George TJ, et al. Outcomes of isolated tricuspid valve surgery have improved in the modern era. Ann Thorac Surg 2019;108:11–5. https://doi.org/10.1016/j.athoracsur.2019.03.004 746. Russo M, Di Mauro M, Saitto G, Lio A, Berretta P, Taramasso M, et al. Outcome of patients undergoing isolated tricuspid repair or replacement surgery. Eur J Cardiothorac Surg 2022;62:ezac230. https://doi.org/10.1093/ejcts/ezac230 747. Abdelbar A, Kenawy A, Zacharias J. Minimally invasive tricuspid valve surgery. J Thorac Dis 2021;13:1982–92. https://doi.org/10.21037/jtd-20-1331 748. Taramasso M, Benfari G, van der Bijl P, Alessandrini H, Attinger-Toller A, Biasco L, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol 2019;74:2998–3008. https://doi.org/10.1016/j.jacc.2019. 09.028 749. Kodali S, Hahn RT, Makkar R, Makar M, Davidson CJ, Puthumana JJ, et al. Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study. Eur Heart J 2023;44:4862–73. https://doi.org/10.1093/eurheartj/ehad667 750. Donal E, Sitges M, Panis V, Schueler R, Lapp H, Moellmann H, et al. Characterization of tricuspid valve anatomy and coaptation gap in subjects receiving tricuspid transcatheter edge-to-edge repair: observations from the bRIGHT TriClip study. J Am Soc Echocardiogr 2024;37:397–404. https://doi.org/10.1016/j.echo.2023.12.002 751. Wild MG, Löw K, Rosch S, Gercek M, Higuchi S, Massberg S, et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation. JACC Cardiovasc Interv 2022;15:1352–63. https://doi.org/10.1016/j.jcin.2022.05. 041 752. Sarralde JA, Bernal JM, Llorca J, Pontón A, Diez-Solorzano L, Giménez-Rico JR, et al. Repair of rheumatic tricuspid valve disease: predictors of very long-term mortality and reoperation. Ann Thorac Surg 2010;90:503–8. https://doi.org/10.1016/j. athoracsur.2010.03.105 753. Saran N, Dearani JA, Said SM, Greason KL, Pochettino A, Stulak JM, et al. Long-term outcomes of patients undergoing tricuspid valve surgery. Eur J Cardiothorac Surg 2019;56:950–8. https://doi.org/10.1093/ejcts/ezz081 754. McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al. Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional surgical bioprosthetic valves: an international, multicenter registry study. Circulation 2016;133:1582–93. https://doi.org/10.1161/CIRCULATIONAHA.115.019353 755. Pereyra M, Farina JM, Chao CJ, Ayoub C, Arsanjani R. Percutaneous transcatheter pulmonary and tricuspid valve replacements in a patient with carcinoid heart disease. Eur Heart J Case Rep 2023;7:ytad511. https://doi.org/10.1093/ehjcr/ytad511 756. Connolly HM, Schaff HV, Abel MD, Rubin J, Askew JW, Li Z, et al. Early and late outcomes of surgical treatment in carcinoid heart disease. J Am Coll Cardiol 2015;66: 2189–96. https://doi.org/10.1016/j.jacc.2015.09.014 757. Yunoki K, Naruko T, Itoh A, Ohashi J, Fujimoto K, Shirai N, et al. Percutaneous transcatheter balloon valvuloplasty for bioprosthetic tricuspid valve stenosis. Circulation 2006;114:e558–9. https://doi.org/10.1161/CIRCULATIONAHA.106.618611 758. Tribouilloy C, Bohbot Y, Kubala M, Ruschitzka F, Popescu B, Wendler O, et al. Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey. Eur Heart J 2022;43:2756–66. https://doi.org/10.1093/ eurheartj/ehac209 759. Iung B, Baron G, Tornos P, Gohlke-Bärwolf C, Butchart EG, Vahanian A. Valvular heart disease in the community: a European experience. Curr Probl Cardiol 2007;32:609–61. https://doi.org/10.1016/j.cpcardiol.2007.07.002 760. Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015;107:djv008. https://doi.org/10.1093/jnci/djv008 761. Unger P, Pibarot P, Tribouilloy C, Lancellotti P, Maisano F, Iung B, et al. Multiple and mixed valvular heart diseases. Circ Cardiovasc Imaging 2018;11:e007862. https://doi. org/10.1161/CIRCIMAGING.118.007862 762. Ajmone Marsan N, Delgado V, Shah DJ, Pellikka P, Bax JJ, Treibel T, et al. Valvular heart disease: shifting the focus to the myocardium. Eur Heart J 2023;44:28–40. https://doi. org/10.1093/eurheartj/ehac504 763. de Marchi SF, Windecker S, Aeschbacher BC, Seiler C. Influence of left ventricular relaxation on the pressure half time of aortic regurgitation. Heart 1999;82:607–13. https://doi.org/10.1136/hrt.82.5.607 764. Unger P, Tribouilloy C. Aortic stenosis with other concomitant valvular disease: aortic regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation. Cardiol Clin 2020;38:33–46. https://doi.org/10.1016/j.ccl.2019.09.002 765. Unger P, Clavel M-A. Mixed aortic valve disease: a diagnostic challenge, a prognostic threat. Structural Heart 2020;4:468–74. https://doi.org/10.1080/24748706.2020. 1817643 766. Flachskampf FA, Weyman AE, Gillam L, Liu CM, Abascal VM, Thomas JD. Aortic regurgitation shortens Doppler pressure half-time in mitral stenosis: clinical evidence, in vitro simulation and theoretic analysis. J Am Coll Cardiol 1990;16:396–404. https://doi. org/10.1016/0735-1097(90)90592-d 767. Tribouilloy C, Shen WF, Rey JL, Adam MC, Lesbre JP. Mitral to aortic velocity-time integral ratio: a non-geometric pulsed-Doppler regurgitant index in isolated pure mitral regurgitation. Eur Heart J 1994;15:1335–9. https://doi.org/10.1093/oxfordjournals. eurheartj.a060390 768. Benfari G, Clavel M-A, Nistri S, Maffeis C, Vassanelli C, Enriquez-Sarano M, et al. Concomitant mitral regurgitation and aortic stenosis: one step further to low-flow preserved ejection fraction aortic stenosis. Eur Heart J Cardiovasc Imaging 2018;19: 569–73. https://doi.org/10.1093/ehjci/jex172 769. Mohan JC, Mukherjee S, Kumar A, Arora R, Patel AR, Pandian NG. Does chronic mitral regurgitation influence Doppler pressure half-time–derived calculation of the mitral valve area in patients with mitral stenosis? Am Heart J 2004;148:703–9. https://doi. org/10.1016/j.ahj.2003.12.043 770. Hauge SW, Estensen ME, Persson R, Abebe S, Mekonnen D, Nega B, et al. The importance of concomitant mitral regurgitation for estimates of mitral valve area by pressure half time in patients with chronic rheumatic heart disease. Int J Cardiol 2024;398: 131600. https://doi.org/10.1016/j.ijcard.2023.131600 771. Dahou A, Magne J, Clavel MA, Capoulade R, Bartko PE, Bergler-Klein J, et al. Tricuspid regurgitation is associated with increased risk of mortality in patients with low-flow low-gradient aortic stenosis and reduced ejection fraction: results of the multicenter TOPAS study (True or Pseudo-Severe Aortic Stenosis). JACC Cardiovasc Interv 2015; 8:588–96. https://doi.org/10.1016/j.jcin.2014.08.019 772. Shiran A, Sagie A. Tricuspid regurgitation in mitral valve disease: incidence, prognostic implications, mechanism, and management. J Am Coll Cardiol 2009;53:401–8. https:// doi.org/10.1016/j.jacc.2008.09.048 773. Naeije R, Badagliacca R. The overloaded right heart and ventricular interdependence. Cardiovasc Res 2017;113:1474–85. https://doi.org/10.1093/cvr/cvx160 774. Furukawa A, Abe Y, Ito K, Hosogi S, Yamamoto K, Ito H. Mechanisms of changes in functional mitral regurgitation by preload alterations. J Cardiol 2018;71:570–6. https://doi.org/10.1016/j.jjcc.2017.12.005 775. Wunderlich NC, Beigel R, Siegel RJ. Management of mitral stenosis using 2D and 3D echo-Doppler imaging. JACC Cardiovasc Imaging 2013;6:1191–205. https://doi.org/10. 1016/j.jcmg.2013.07.008 Downloaded from academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 07 October 2026